A Bayesian dose‐finding design for phase I/II clinical trials with nonignorable dropouts

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0258|34|10|1721-1732

ISSN： 0277-6715

Source： STATISTICS IN MEDICINE, Vol.34, Iss.10, 2015-05, pp. : 1721-1732

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A comparative study of adaptive dose‐finding designs for phase I oncology trials of combination therapies

By  

STATISTICS IN MEDICINE, Vol. 34, Iss. 24, 2015-10 ,pp. : 3194-3213

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose finding with continuous outcome in phase I oncology trials

By  

PHARMACEUTICAL STATISTICS: THE JOURNAL OF APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY, Vol. 14, Iss. 2, 2015-03 ,pp. : 102-107

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bayesian optimal interval designs for phase I clinical trials

By  

JOURNAL OF THE ROYAL STATISTICAL SOCIETY: SERIES C (APPLIED STATISTICS), Vol. 64, Iss. 3, 2015-04 ,pp. : 507-523

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time‐to‐event endpoints

By  

STATISTICS IN MEDICINE, Vol. 34, Iss. 11, 2015-05 ,pp. : 1889-1903

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bayesian sequential monitoring design for two‐arm randomized clinical trials with noncompliance

By  

STATISTICS IN MEDICINE, Vol. 34, Iss. 13, 2015-06 ,pp. : 2104-2115

John Wiley & Sons Inc

Access to resources Recommend Favorite